Premium
Central nervous system involvement in non‐Hodgkin's lymphoma: An analysis of 105 cases
Author(s) -
Mackintosh F. Roy,
Colby Thomas V.,
Podolsky William J.,
Burke Jerome S.,
Hoppe Richard T.,
Rosenfelt Fred P.,
Rosenberg Saul A.,
Kaplan Henry S.
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19820201)49:3<586::aid-cncr2820490331>3.0.co;2-c
Subject(s) - medicine , lymphoma , hodgkin lymphoma , central nervous system , pathology , nervous system , psychiatry
Records of 105 patients with central nervous system (CNS) lymphoma were analyzed in order to better define the incidence, setting, and management of CNS lymphoma and the role for CNS prophylaxis. Survival was best for patients under 30 years of age treated with whole‐brain irradiation and intrathecal (IT) chemotherapy whose CNS involvement was an isolated event (median survival time, 1.8 years). Survival was worst for patients over 30 years of age whose CNS invasion occurred at a time of progressive systemic lymphoma (median time ten weeks if treated with whole‐brain irradiation with or without IT chemotherapy). The risk of CNS invasion was greatest for those with lymphoblastic lymphoma. Among patients with Stage IIE, III, or IV histiocytic lymphoma, the risk of CNS involvement was greatest for those with progressive or relapsing disease or involvement of the testes, peripheral blood, or epidural space of the spinal cord.